Project Grant R01AI189589
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $566,875 to the La Jolla Institute for Immunology under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 18, 2026, with a completion date of January 31, 2028. Under this award, Dr. Vijayanand's research team will conduct scientific research to deorphanize a novel G-protein coupled receptor (GPCR) expressed by tissue-resident memory T cells (TRM...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Chicago a $807,799 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 15, 2025, with a completion date of June 30, 2030. This award supports fundamental immunological research investigating B cell-dependent regulatory T (Treg) cells and their role in controlling self-reactive B cells and autoantibody production. The research...
- Federal Grant Award Summary The University of California, San Diego received a $3.02 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 8, 2025, with a completion date of June 30, 2029. This award funds a four-year basic science research project investigating the regulatory T (Treg) cell-derived interleukin-27 (IL-27) axis and its role in immune regulation, particularly in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $463,676 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore on August 7, 2025, with a completion date of July 31, 2030. This research project delivers comprehensive scientific investigation into the mechanisms of Fc-mediated effector functions in response to viral surface proteins, with particular emphasis on...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $438,500 to the University of California, San Diego for a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 8, 2025, with a completion date of June 30, 2027. The research project focuses on characterizing sequence-specific determinants and impacts of NS2 (non-structural protein 2) interactions with the influenza A virus (IAV) polymerase...
- Federal Grant Award Summary The University of California, San Diego received a $3.19 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 16, 2025, with a completion date of June 30, 2029. This award supports biomedical research investigating the roles and regulation of tissue-resident CD8 T cells during persistent viral infections, specifically utilizing a mouse...
- Federal Project Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 8, 2025, with a completion date of June 30, 2027. This research project investigates the fundamental mechanisms underlying immunoglobulin gene rearrangement, specifically focusing on how enhancers and epigenetic modifications...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $659,663 to the Beckman Research Institute of the City of Hope under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 1, 2025, for a five-year project period concluding July 31, 2030. This Project Grant funds biomedical research investigating the role of RNA modification in innate immune cell development and function, specifically examining how the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Alabama a Project Grant totaling $431,147 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period July 1, 2025 through June 30, 2027. This research project investigates the innate immune mechanisms underlying monoclonal antibody (MAb)-induced infusion reactions (IRs), which are adverse immune events that occur within 30–120 minutes of...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $448,375 to Northern California Institute For Research And Education, Inc. (NCIRE) on September 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct biomedical research examining proteoglycan 4 (PRG4/lubricin) glycoform variants associated with endocardial infections and sepsis. The research project, which extends through August 31, 2027, will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $890,877 to the La Jolla Institute for Immunology under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 1, 2026 through January 31, 2031. The research project, conducted in La Jolla, California, focuses on illuminating the immunoregulatory mechanisms of Interleukin-1 Receptor 8 (IL-1R8) and developing novel therapeutic strategies. The institute will deliver high-resolution structural analyses of IL-1R8 in complex with pro-inflammatory receptors at the atomic level, characterize IL-1R8-targeting monoclonal antibodies derived from engineered immunogens, and design and evaluate novel biological drug candidates targeting IL-1R8. This research addresses a critical gap in understanding how IL-1R8 functions as a dual-mechanism immunoregulatory factor—both blocking pro-inflammatory signals and transducing anti-inflammatory signaling. By combining structural biology, antibody discovery and optimization, and rational drug design approaches, the project aims to establish a scientific foundation for developing therapeutics that can selectively modulate immune responses to treat chronic inflammatory diseases, autoimmune disorders, and enhance anti-cancer immunity.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $890.9k | 2/1/26 |